Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

European Journal of Cancer

Volumn 82, Issue , 2017, Pages 34-44

  Le Burel, Sébastien ^a   Champiat, Stéphane ^b,c   Mateus, Christine ^b   Marabelle, Aurélien ^b,c   Michot, Jean Marie ^b   Robert, Caroline ^b   Belkhir, Rakiba ^a   Soria, Jean Charles ^b,c   Laghouati, Salim ^b   Voisin, Anne Laure ^b   Fain, Olivier ^d   Mékinian, Arsène ^d   Coutte, Laetitia ^e   Szwebel, Tali Anne ^e   Dunogeant, Laetitia ^f   Lioger, Bertrand ^g   Luxembourger, Cécile ^h   Mariette, Xavier ^a,i,j   Lambotte, Olivier ^a,i,j,k  

^a BICÊTRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Universite Paris Sud   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e Institut Cochin   (France)

^f Hematology Oncology Day Hospital   (France)

^g CHU BRETONNEAU   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ INSERM   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

more..

Author keywords

Connective tissue diseases; Immune thrombocytopenia; Immunotherapy; Rheumatic diseases

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTAGONIST; DURVALUMAB; IMMUNOGLOBULIN G; IPILIMUMAB; METHOTREXATE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1 ANTAGONIST; PROGRAMMED DEATH 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; COLITIS; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPOPHYSITIS; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PNEUMONIA; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SJOEGREN SYNDROME; THROMBOCYTOPENIA; THYROIDITIS; VERY ELDERLY; VITILIGO; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; FRANCE; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASMS; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; FRANCE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MIDDLE AGED; NEOPLASMS; PREVALENCE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85021128995     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.032     Document Type: Article

References (49)

1. Baumeister, S.H., Freeman, G.J., Dranoff, G., Sharpe, A.H., Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 34 (2016), 539–573.
2. Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 2016:54 (1990), 139–148.
3. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
4. Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P., Chandra, A.B., Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol, 8, 2017, 49.
5. Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113 (2009), 2386–2393.
6. Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H.M., Alexander, E.L., Carsons, S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002), 554–558.
7. Shiboski, C.H., Shiboski, S.C., Seror, R., Criswell, L.A., Labetoulle, M., Lietman, T.M., et al. 2016 American College of Rheumatology/European League against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76 (2017), 9–16.
8. Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (1975), 344–347.
9. Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 62 (2010), 2569–2581.
10. Dasgupta, B., Cimmino, M.A., Kremers, H.M., Schmidt, W.A., Schirmer, M., Salvarani, C., et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 64 (2012), 943–954.
11. Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., Mielants, H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54 (2006), 2665–2673.
12. Le Burel, S., Champiat, S., Routier, E., Aspeslagh, S., Albiges, L., Szwebel, T.-A., et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis, 2017 Feb 27, 10.1136/annrheumdis-2016-210820 pii: annrheumdis-2016-210820. [Epub ahead of print].
13. Le Roy, A., Kempf, E., Ackermann, F., Routier, E., Robert, C., Turpin, A., et al. Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer Oxf Engl 2016:54 (1990), 172–174.
14. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
15. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
16. Ahmad, S., Lewis, M., Corrie, P., Iddawela, M., Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract 18 (2012), 287–292.
17. Kopecký, J., Trojanová, P., Kubeček, O., Kopecký, O., Treatment possibilities of ipilimumab-induced thrombocytopenia–case study and literature review. Jpn J Clin Oncol 45 (2015), 381–384.
18. Simeone, E., Grimaldi, A.M., Esposito, A., Curvietto, M., Palla, M., Paone, M., et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep, 8, 2014, 240.
19. Shiuan, E., Beckermann, K.E., Ozgun, A., Kelly, C., McKean, M., McQuade, J., et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer, 5, 2017, 8.
20. Kanameishi, S., Otsuka, A., Nonomura, Y., Fujisawa, A., Endo, Y., Kabashima, K., Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 27 (2016), 546–547.
21. Kong, B.Y., Micklethwaite, K.P., Swaminathan, S., Kefford, R.F., Carlino, M.S., Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 26 (2016), 202–204.
22. Schwab, K.S., Heine, A., Weimann, T., Kristiansen, G., Brossart, P., Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and Chronic Lymphatic Leukemia. Case Rep Oncol 9 (2016), 373–378.
23. Tardy, M.P., Gastaud, L., Boscagli, A., Peyrade, F., Gallamini, A., Thyss, A., Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report. Hematol Oncol, 2016 Aug 19, 10.1002/hon.2338 [Epub ahead of print].
24. Cappelli, L.C., Gutierrez, A.K., Bingham, C.O., Shah, A.A., Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res, 2016 Dec 20, 10.1002/acr.23177 [Epub ahead of print].
25. Syrigos, K., Tsagouli, S., Grapsa, D., Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: a case report. Ann Intern Med 165 (2016), 894–895.
26. Gutzmer, R., Koop, A., Meier, F., Hassel, J.C., Terheyden, P., Zimmer, L., et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer Oxf Engl 2017:75 (1990), 24–32.
27. Kimura, T., Fukushima, S., Miyashita, A., Aoi, J., Jinnin, M., Kosaka, T., et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107 (2016), 1055–1058.
28. Zimmer, L., Goldinger, S.M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer Oxf Engl, 1990, 2016.
29. Behling, J., Kaes, J., Münzel, T., Grabbe, S., Loquai, C., New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27:2 (2017), 155–158.
30. Yoshioka, M., Kambe, N., Yamamoto, Y., Suehiro, K., Matsue, H., Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 42 (2015), 1008–1009.
31. Hunter, G., Voll, C., Robinson, C.A., Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci J Can Sci Neurol 36 (2009), 518–520.
32. Sheik Ali, S., Goddard, A.L., Luke, J.J., Donahue, H., Todd, D.J., Werchniak, A., et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151 (2015), 195–199.
33. Bilen, M.A., Subudhi, S.K., Gao, J., Tannir, N.M., Tu, S.-M., Sharma, P., Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer, 4, 2016, 36.
34. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
35. Law-Ping-Man, S., Martin, A., Briens, E., Tisseau, L., Safa, G., Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatol Oxf Engl 55 (2016), 2087–2089.
36. Bonigen, J., Raynaud-Donzel, C., Hureaux, J., Kramkimel, N., Blom, A., Jeudy, G., et al. Anti-PD1-induced psoriasis. A study of 21 patients. J Eur Acad Dermatol Venereol JEADV 31:5 (2016), e254–e257.
37. Cappelli, L.C., Gutierrez, A.K., Baer, A.N., Albayda, J., Manno, R.L., Haque, U., et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:1 (2017), 43–50.
38. Chan, M.M.K., Kefford, R.F., Carlino, M., Clements, A., Manolios, N., Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother Hagerst Md 2015:38 (1997), 37–39.
39. Suozzi, K.C., Stahl, M., Ko, C.J., Chiang, A., Gettinger, S.N., Siegel, M.D., et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2 (2016), 264–268.
40. Montaudié, H., Pradelli, J., Passeron, T., Lacour, J.-P., Leroy, S., Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 176:4 (2017), 1060–1063.
41. Schubert, D., Bode, C., Kenefeck, R., Hou, T.Z., Wing, J.B., Kennedy, A., et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20 (2014), 1410–1416.
42. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
43. Johnson, D.B., Friedman, D.L., Berry, E., Decker, I., Ye, F., Zhao, S., et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single Referral center. Cancer Immunol Res 3 (2015), 464–469.
44. Weber, J.S., Hodi, F.S., Wolchok, J.D., Topalian, S.L., Schadendorf, D., Larkin, J., et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35 (2017), 785–792.
45. Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:2 (2017), 368–376.
46. Johnson, D.B., Sullivan, R.J., Ott, P.A., Carlino, M.S., Khushalani, N.I., Ye, F., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2 (2016), 234–240.
47. Chiarion-Sileni, V., Pigozzo, J., Ascierto, P.A., Simeone, E., Maio, M., Calabrò, L., et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 110 (2014), 1721–1726.
48. Lebbé, C., Weber, J.S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 25 (2014), 2277–2284.
49. Brunot, A., Jeudy, G., Tas, M., Guillot, B., Kramkimel, N., Mortier, L., et al. Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients. J Clin Oncol [Internet], 2016 [cited 2017 Jan 15];34. Available from: http://meetinglibrary.asco.org/content/168789-176.